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BRCA1 is a susceptibility gene for breast and ovarian cancer with
growth-inhibitory activity for which the mechanism of action
remains unclear. When introduced into cells, BRCA1 inhibits
growth of some but not all cell lines. In an attempt to uncover the
mechanism of growth suppression by BRCA1, we examined a panel
of cell lines for their ability to reduce colony outgrowth in response
to BRCA1 overexpression. Of all variables tested, only those cells
with wild-type pRb were sensitive to BRCA1-induced growth
suppression. In cells with an intact rb gene, inactivation of pRb by
HPV E7 abrogates the growth arrest imposed by BRCA1. In accor-
dance with these observations, we found that BRCA1 could not
suppress BrdUrd uptake in primary fibroblasts from rb2/2 mice
and exhibited an intermediate ability to inhibit DNA synthesis in
rb1/2 as compared with rb1/1 cells. We further found that the
BRCA1 protein complexes with the hypophosphorylated form of
pRb. This binding is localized to amino acids 304–394 of BRCA1
protein and requires the ABC domain of pRb. In-frame deletion of
BRCA1 fragment involved in interaction with pRb completely
abolished the growth-suppressive property of BRCA1. Although it
has been reported that BRCA1 interacts with p53, we find the p53
status did not affect the ability of BRCA1 to suppress colony
formation. Our data suggest that the growth suppressor function
of BRCA1 depends, at least in part, on Rb.
Germline mutations in BRCA1 are found in '50–60% ofhereditary breast and ovarian cancers (1). Despite the
unequivocal role of BRCA1 in familial breast cancer suscepti-
bility, the biological function of the BRCA1 protein remains
unclear. Experimental data suggest that BRCA1 may be a
negative regulator of cell growth. Attenuation of BRCA1 syn-
thesis by antisense oligonucleotide increased the proliferative
rate of both benign and malignant mammary epithelial cells in
culture (2), and BRCA1 expression decreased the capacity of
MCF7 breast cancer cells to form tumors in nude mice (3).
However, BRCA1 expression increases as cells progress through
the G1 and S phases of the cell cycle (4, 5). Furthermore,
homozygous BRCA1 mutant mice died at day 7.5 of embryo-
genesis with evidence of abnormal cessation of cellular prolif-
eration accompanied by high levels of the CDK inhibitor p21 and
low levels of cyclin E and mdm2 (6, 7). Recently, colocalization
and physical interaction of BRCA1 with Rad51 protein has
raised the possibility that BRCA1 is involved in DNA repair (8).
Moreover, the COOH terminus of the BRCA1 protein can
activate transcription in in vitro experiments (9, 10) and coacti-
vate transcription of p53-regulated genes (11, 12).
The experimental biology of BRCA1 therefore suggests that
BRCA1 may have different functions, each best manifested in
specific study systems and cell lines. Herein, we show that
BRCA1 binds preferentially to the hypophosphorylated form of
Rb and that the growth-suppressive phenotype of BRCA1
depends on the presence of a functional Rb protein. These data
indicate the complexity of BRCA1 action given its reliance on
other molecules to induce a biological response.
Methods
Cells and Cell Culture. Mcf7 (breast carcinoma) and HBL100
(normal breast epithelial cells immortalized with SV40) were
obtained from the Tissue Culture Facility, Lineberger Cancer
Center, University of North Carolina at Chapel Hill. U2OS,
SaOS2 (osteosarcoma), and HaCaT (immortalized human ker-
atinocytes) were from Y. Xiong (University of North Carolina at
Chapel Hill). UNC7 and JHU012 (head and neck cancer) were
a gift from W. Yarbrough (University of North Carolina at
Chapel Hill). H2009 (lung cancer) was obtained from F. Kaye
(National Cancer Institute, Bethesda). Mouse embryo fibro-
blasts derived from Rb1/2 and Rb2/2 as well as wild-type
control were from Tyler Jacks (Massachusetts Institute of Tech-
nology, Boston).
Plasmid Constructs. Amino acids 303–394 were deleted from
BRCA1 protein with the GeneEditor in vitro site-directed mu-
tagenesis system (Promega) with the use of oligonucleotide
59-CCCATCATGTGAGTCATCAGAAGCCTTTTCTACAT-
TCATTCT-39 according to manufacturer’s instructions. COOH-
terminal truncation of BRCA1 was made by deletion from
internal ApaI to the ApaI site in the polylinker region of pcDNA3
vector.
Glutathione S-Transferase (GST) Protein Purification and GST Pull-
Down Assay. Glutathione–Sepharose 4B was purchased from
Pharmacia, and recombinant GST fusion proteins were purified
according to the manufacturer’s instructions. Purified GST
fusion proteins attached to beads were equalized by protein
amount with Coomassie-stained gel, and the total amount of
beads was balanced with naked glutathione–Sepharose beads.
Approximately 2 mg of purified GST fusion proteins was used per
reaction.
For experiments shown in Fig. 6, '1 mg of corresponding
plasmid was in vitro translated in presence of [35S]methionine
with a TNT kit (Promega) according to the manufacturer’s
instruction. For the control of protein synthesis, 2 ml of each
reaction was loaded in lanes labeled IVT. Ten microliters of the
reaction mixture was diluted in binding buffer (50 mM TriszHCl,
pH 7.5/150 mM NaCl/0.5% Nonidet P-40/50 mM NaF/25 mg/ml
aprotinin/25 mg/ml leupeptin/1 mM benzamidine/1 mM DTT),
combined with GST fusion protein-coated beads, and rotated for
1 h at 4°C. Beads were washed five times with binding buffer,
boiled with 50 ml of loading dye, and separated by PAGE (10%
gel). Proteins were visualized with autoradiography.
For protein pull-down assay presented in Fig. 7, '2 3 107
U2OS or SK-N-SH cells were used per reaction. Cells were lysed
in HNTG buffer (20 mM TriszHCl, pH 8.0/150 mM NaCl/1.5 mM
MgCl2/0.2 mM EDTA/10% glycerol/0.5% NP-40/50 mM NaF/
protease inhibitors as above) for 30 min, centrifuged for 10 min
at 11,000 3 g, and incubated with beads coated with different
GST fusion proteins balanced by the amount of protein as
described above. After 2 h, the beads were washed five times with
HNTG buffer, boiled with 50 ml of Laemmli sample buffer, and
Abbreviations: GST, glutathione S-transferase; b-gal, b-galactosidase.
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loaded onto 6% PAGE gels. Proteins were visualized by Western
blotting with anti-BRCA1 antibody C-20 (Santa Cruz) or an-
ti-Rb G3-245 (PharMingen).
To prove that BRCA1 specifically binds to GST-Rb ABC
protein, the beads after pull-down reaction were treated with 20
mM glutathione for 10 min at room temperature to disrupt the
interaction of GST with the beads, washed once, and boiled with
50 ml of loading dye as above.
Immunoprecipitation and Western Blotting. To coimmunoprecipi-
tate the endogenous BRCA1-pRb complex, '4 3 107 U2OS
cells were used for one reaction. Cells were lysed with modified
HNTG buffer that contained 1.5 mM ZnCl2 but no NP-40 and
disrupted by sonication in an Ultrasonic processor (Misonix,
Farmingdale, NY). BRCA1 was immunoprecipitated with 4 mg
of anti-BRCA1 antibody (MS110, Calbiochem) in the presence
of protein A/G-Sepharose (Santa Cruz) overnight. Rb was
immunoprecipitated with either 40 ml of agarose-conjugated
C-36 antibody (Calbiochem) or 4 mg of anti-Rb C-15 antibody
(Santa Cruz) with protein A–Sepharose (Pierce). Immune com-
plexes were washed five times with lysis buffer plus 0.5% NP-40
and resolved on a 6% gel for BRCA1.
Transfections and Immunohistochemical Staining. For transfection,
cells were split the day before in 60-mm plates and transfected
at '60% confluency with Lipofectamine reagent (GIBCO/
BRL) according to manufacturer’s instructions. To achieve an
equimolar amount of transfected DNA, 5 mg of pcDNA3-
BRCA1 or 2.5 mg of pcDNA3 (Invitrogen) was used. The total
amount of DNA was balanced with carrier DNA. In 2 days, cells
were split at different dilutions into selection media containing
G-418. From 2 to 3 weeks later, colonies were stained with
crystal violet and counted.
For transfection of the U2OS or HBL100 cell lines with
linearized plasmids, 20 mg of pcDNA3-BRCA1 vector was
digested with either PvuI or HindIII–AflII restriction enzymes.
Completeness of digestion was verified by gel electrophoresis.
DNA was ethanol-precipitated and dissolved in 10 mM Tris/1
mM EDTA buffer, pH 8.0, and the concentration was deter-
mined. Five micrograms of each sample was transfected by using
Lipofectamine reagent (GIBCO/BRL).
U2OS cells expressing HPV16-E7 were obtained by transfec-
tion with pCEP4-E7 plasmid (Y. Xiong, University of North
Carolina at Chapel Hill), cells were selected with 200 mg/ml
hygromycin, and resistant clones were pooled and maintained in
selection media. Expression of E7 protein was verified by reverse
transcription–PCR.
U2OS cells overexpressing p53Val135 mutant were produced
by cotransfection with LTRp53cG(val) (13) and pLXSP carrying
the puromycin resistance gene. Clones were selected in 1 mg/ml
puromycin, and the clone expressing the highest level of p53 was
selected for further analysis. To test whether p53 function has
been compromised in this clone, cells were treated with 0.34 mM
Adriamycin (Sigma) for 18–24 h, and p53 and p21 protein
induction was analyzed by Western blotting.
Mouse embryo fibroblasts on 60-mm plates were cotrans-
fected with 1 mg of CMV-lacZ and 6 mg of BRCA1 expression
vector or 3 mg of empty vector by using Lipofectamine Plus
reagent (GIBCO/BRL). At 48 h, BrdUrd was added for 12 h.
Cells were fixed with 3.7% formaldehyde for 10 min, perme-
abilized with 0.2% Triton X-100, and stained for b-galactosidase
(b-gal) by using a b-gal staining kit (Invitrogen). Histochemical
detection of BrdUrd incorporation was done with a cell prolif-
eration kit (Amersham), which uses monoclonal anti-BrdUrd
antibody and secondary anti-mouse horseradish peroxidase con-
jugate.
Adenovirus-Mediated BRCA1 Overexpression. Recombinant adeno-
viruses were made according the procedure described by He et
al. (14). U2OS and HBL100 cells were split the day before the
infection at 0.6 3 106 cells per 100-mm plate and infected at
multiplicity of infection of 500 plaque-forming units/cell for
U2OS or 1,000 plaque-forming units/cell for HBL100. Cell cycle
distribution was tested 3 days after infection by using FACscan
(Becton Dickinson). Nocodazole was added to the cell culture
12 h before fixation at a concentration of 40 ng/ml.
Results
BRCA1 Suppresses Growth of Rb-Positive Cell Lines. It has been
reported that elevated level of BRCA1 inhibits growth of breast
and ovarian but not lung or colon cancer cell lines (3). We,
however, noticed that a number of other cell lines were also
growth-arrested when the BRCA1 gene was overexpressed. To
examine what cellular background may affect BRCA1 function,
we transfected BRCA1 into panel of cell lines with known status
of the major growth-regulatory genes, such as p53, pRb. Cells
transfected with a BRCA1 expression vector or an equimolar
amount of vector alone were selected with G-418 and colonies
were stained and counted in 2–3 weeks. Of all variables tested,
only Rb status correlated with BRCA1-induced growth suppres-
sion. Overexpression of BRCA1 in cells with wild-type pRb
resulted in a 50–65% reduction in the number of colonies
compared with vector alone (Fig. 1). Three cell lines with either
a deletion in the Rb gene (SaOS2 and H2009) or inactivation of
pRb because of the presence of SV40 (HBL100) showed no
difference in the number of colonies after transfection with
BRCA1 compared with the control.
The colony formation assay used in our studies is based on the
comparison of the number of colonies originated by cells trans-
fected with the BRCA1 expression vector (pcDNA3-BRCA1)
and an equimolar amount of empty vector (pcDNA3). This is
accurate only if we assume that plasmids of different molecular
weight (pcDNA3 and pcDNA3-BRCA1) will be transfected into
the cell with the same efficiency. To validate the method, we
performed colony formation assays by using pcDNA3-BRCA1
to achieve both the BRCA1 baseline and the BRCA1-
Fig. 1. Growth suppression by BRCA1. Cells were transfected with equimolar
amounts of pcDNA3-BRCA1 or vector alone and selected with G-418; emerg-
ing colonies were stained and counted. The number of colonies obtained with
the vector alone was considered as 100%. pRb and p53 status of cells is shown.
Each experiment was repeated at least three times, and error bars represent
standard deviation. ■, vector alone transfections; h, BRCA1 transfections. p,
HBL100 cell line is SV40-positive; ND, not done.








overexpressed state. Overexpression was obtained by cleaving
the pcDNA3-BRCA1 plasmid at the unique PvuI site within the
ampicillin resistance gene (Fig. 2A). As a negative control, the
same plasmid was digested with HindIII, which is located
between promoter and the ORF, and AflII, which cuts the
plasmid within the BRCA1 gene at nucleotide 1538. This double
cleavage eliminates the likelihood of recreating the intact ex-
pression vector if the plasmid incorporates as tandem repeats in
the appropriate orientation. The expression of BRCA1 protein
after transfection with DNA linearized with PvuI, but not
double-digested with HindIII–AflII, was confirmed by transfec-
tion of Cos7 cells (Fig. 2B). By using this approach, overexpres-
sion of BRCA1 protein again resulted in reduction of colony
number when transfected into the U2OS cell line but not into the
HBL100 cell line (Fig. 2C).
Inactivation of pRb with the E7 Oncoprotein Abrogates BRCA1-
Mediated Growth Suppression. The human papilloma virus onco-
protein, E7, binds to and inactivates pRb. To prove that the
presence of functional Rb protein is critical for growth suppres-
sion by BRCA1, we produced U2OS cells stably expressing E7
protein and transfected them with pcDNA3-BRCA1 vector
digested with either HindIII–AflII or PvuI as described above.
We found that in the presence of E7 protein, BRCA1 was not
able to suppress cell growth (Fig. 2C).
BRCA1 Suppresses Growth of rb1/1, but Not rb2/2, Mouse Embryo
Fibroblasts. Our results show that BRCA1 growth arrest depends
on the presence of functional Rb protein. These results are based
on the study of immortal cell lines that may accumulate multiple
unknown mutations during propagation in vitro. Although the
inactivation of pRb protein by coexpression with HPV-E7 also
confirms the importance of Rb for BRCA1-induced growth
arrest, the E7 protein also inhibits other members of the Rb
family, p107 and p130 (15, 16). To resolve these questions, we
used isogenic cells derived from mouse embryo fibroblasts with
targeted disruption of the rb gene, as well as primary fibroblasts
derived from mouse embryos heterozygous for rb deletion, and
compared them with cells from normal embryos. These primary
fibroblasts (gift of Tyler Jacks) were cotransfected with the lacZ
expression vector (as a transfection marker) and an excess of a
BRCA1-containing plasmid or vector control and assessed for
BrdUrd uptake as a marker of cell proliferation (Fig. 3). When
the BRCA1 gene was overexpressed in Rb1/1 mouse embryo
fibroblasts, we observed a 45% decrease in the number of
proliferating cells compared with transfection with vector alone.
In Rb1/2 cells, the decrease in proliferating cells was 22%, and
in Rb2/2 cells, BRCA1 overexpression did not affect BrdUrd
uptake. These results therefore confirm that the presence of the
Rb protein, and not Rb-related proteins such as p107 and p130,
is important for the BRCA1-induced growth arrest.
BRCA1 Growth Suppression Is p53 Independent. It has been shown
that, in the presence of p53, BRCA1 protein can coactivate
transcription of p53-responsive elements (11, 12). Therefore, we
originally expected that not only would Rb status affect BRCA1-
imposed growth suppression but also the absence of p53 might
have an impact on BRCA1 growth effects. However, several cell
lines in our panel (Fig. 1) had a normal Rb and a mutated p53
gene (HaCaT and UNC7), and both of these cell lines showed
suppression of colony formation when BRCA1 was transfected.
To further confirm that BRCA1 can suppress cell growth in the
absence of functional p53, we partially inactivated p53 in U2OS
cell line by overexpression of temperature-sensitive mutant of
      
Fig. 2. Colony formation assay was performed with the pcDNA3-BRCA1
plasmid linearized at different sites for positive and negative control. (A)
Restriction map of the plasmid used in this experiment. (B) Western blot
analysis of BRCA1 expression from differentially cleaved pcDNA3-BRCA1 in
Cos-7 cells. (C) Colony formation assay with linearized plasmids. ■, no BRCA1
control (HindIII–AflII digest). p, overexpression of BRCA1 (PvuI digest).
Fig. 3. Proliferation rate of primary mouse embyo fibroblasts transfected
with BRCA1. Fibroblasts derived from rb1/1, rb2/2, or rb1/2 were cotrans-
fected with a lacZ expression vector and BRCA1 or vector alone. In 2 days, cells
were labeled with BrdUrd and stained for b-gal and BrdUrd. Cells positive for
b-gal were scored for proliferation assessed by BrdUrd incorporation. (A)
Percentage of proliferating cells in the population of transfected cells. (B)
Same as in A with the number of proliferating cells in each cell line transfected
with lacZ and vector alone taken as a 100%. ■, transfection with vector alone;
p, transfection with BRCA1. Standard deviations are presented in A and B. At
least 100 b-gal-positive cells were analyzed in three fields for each transfection
in two independent experiments.
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p53 (p53Val135), which at 37–39°C is acting as a dominant
negative (17). To prove that p53 function was compromised, the
clone of U2OS cells expressing the highest amount of mutant p53
was treated with Adriamycin, and the induction of p53 and p21
proteins was analyzed by Western blotting (Fig. 4B). From 18 to
24 h after treatment, the control cells showed induction of p53
and p21 proteins as compared with untreated cells. However, the
p53val135 clone had almost unchanged levels of p53 and much
lower induction of p21 protein than control cells. When used to
assess colony formation assay after BRCA1 transfection, the
p53val135 clone showed the same growth suppression as the
parental U2OS cell line. By contrast, U2OS cells expressing the
E7 protein showed no inhibition of colony formation (Fig. 4A).
Adenovirus-Mediated BRCA1 Overexpression Induces Accumulation of
Cells in G1 Phase of the Cell Cycle. To confirm our observations by
using other measures of growth inhibition, we infected U2OS
and HBL100 cell lines with adenovirus bearing the BRCA1 or
GFP (used as control) genes. Construction and characterization
of these adenoviruses will be published elsewhere (M.C. and
R.A.J., unpublished work). Approximately the same level of
BRCA1 protein induction ('2- to 3-fold) was found for both cell
lines as measured by Western blotting on the second day after
infection. The status of cell proliferation was monitored by flow
cytometric analysis. We found that BRCA1 induced accumula-
tion of U2OS cells in G0/G1 phase of cell cycle, compared with
the GFP control, 3 days after infection (Fig. 5). This increase in
G0/G1 subpopulation was more obvious when cells were treated
with the mitotic inhibitor nocodazole, which uncovers cells
arrested at G1. No inhibition of cell growth was found when the
HBL100 cell line was infected with the Adeno-BRCA1 virus.
Taken together, these data show that enforced overexpression of
BRCA1 induces a G1 arrest and reduced colony formation in
cells that have an intact pRb.
Interaction of BRCA1 and pRb in Vitro. Our finding that BRCA1 can
exert its effect on cell growth through Rb protein prompted us
to investigate whether interaction between these two proteins
may occur. Indeed, we first found that in vitro-translated full-
length BRCA1 protein was able to bind GST-Rb ABC (amino
acids 379–928) and not GST-Rb C (amino acids 780–928) or the
GST protein alone (Fig. 6B). To localize more precisely the
region of BRCA1 involved in the interaction with pRb, a series
of truncated BRCA1 fragments were tested. The NH2-terminal
394 aa (ScC7 fragment, amino acids 1–394) also showed stable
Fig. 4. BRCA1 overexpression in cells with compromised p53 or pRb. (A)
Colony formation assay of U2OS control cells or U2OS overexpressing
p53Val135 or E7 was performed as in Fig. 1. ■, transfection with vector alone;
u, BRCA1 transfection. (B) Western blot analysis of p53 and p21 proteins
induction 18 h after treatment with Adriamycin.
Fig. 5. Overexpression of BRCA1 results in accumulation of cells in G0/G1.
Cells were infected with recombinant adenovirus bearing either BRCA1 or GFP
gene as control and analyzed by flow cytometry 3 days after infection. (A) Cell
cycle distribution of U2OS and HBL100 cells with or without nocodazole (Noc)
treatment. h, percentage of cells in G0/G1 phase of cell cycle; u, percentage of
cells in S phase of cell cycle; ■, percentage of cells in G2/M phase of cell cycle.
(B) DNA histogram is shown for nocodazole-treated cells described in A. At
least three experiments were performed, and a representative experiment is
shown.








binding to GST-Rb ABC protein (Fig. 6B). However, further
truncation of BRCA1 (N-R, amino acids 1–303) completely
eliminated the interaction with GST-Rb ABC.
On further analysis of the sequences within this 90-aa putative
Rb binding domain, we found an Rb binding motif, LxCxE at
amino acids 358–362. However, when the LxCxE was mutated to
LxPxE or when the pentapeptide was removed by an in-frame
deletion, the BRCA1 binding domain was still able to interact
with pRb (data not shown).
To further demonstrate the binding of pRb to BRCA1, we
reversed the probe and target proteins by using GST fusion
proteins with BRCA1 fragments GST-N-R (amino acids 1–303)
and GST-R-K (amino acids 304–772 shown in Fig. 6A) as probe
proteins and pRb as target. As before, in vitro-translated Rb
protein bound the GST-R-K fragment containing previously
identified pRb binding domain in exon 11, but not with the
GST-N-R protein or GST alone (Fig. 6C). A mutated Rb protein
carrying a C706F missense mutation which does not bind to
oncoproteins E1A and large T antigen but does bind to c-myc
and L-myc (18) also bound to GST-R-K (Fig. 6C).
BRCA1 Protein Binds to the Hypophosphorylated Form of pRb. To
demonstrate that pRb can pull down intact BRCA1, we incu-
bated recombinant GST–Rb proteins with U2OS cellular lysate
and found that only the Rb ABC protein was able to pull down
endogenous BRCA1 (Fig. 7A). Extending this analysis, we
showed that BRCA1 and pRb can be coimmunoprecipitated
from cell extracts by using anti-Rb antibodies (Fig. 7B). In
growing cells, Rb protein is usually present as multiple bands
with the faster migrating form representing the hypophosphor-
ylated protein and the slower migrating forms that are differ-
entially phosphorylated. To identify which species of pRb binds
preferentially to BRCA1, whole cell extracts of SK-N-SH human
neuroblastoma cell line were incubated with the recombinant
GST-BRCA1 proteins described in Fig. 6. Our results show that
only the hypophosphorylated form of pRb affinity precipitates
with GST-R-K fragment (Fig. 7C). Similar results were obtained
when the complex was immunoprecipitated from U2OS cells
(Fig. 7D) by using an anti-BRCA1 antibody.
Deletion of Amino Acids 303–394 from BRCA1 Protein Inactivates Its
Growth-Suppressive Property. To test the biological role of Rb-
BRCA1 interaction, we performed an in-frame deletion of the
92 aa (amino acids 303–394) from BRCA1 which comprised the
putative binding region for Rb protein. When used in colony
formation assay, BRCA1-delta90 had no effect on growth
control (Fig. 8). A construct generating the COOH-terminal
Fig. 6. Identification of BRCA1-Rb interactions. (A) Schematic representa-
tion of BRCA1 fragments used for in vitro translation or GST-fusion proteins.
(B) In vitro-translated [35S]methionine-labeled BRCA1 fragments were incu-
bated with GST–Rb recombinant proteins or GST alone. The complexes were
collected with glutathione–Sepharose and resolved on SDS/PAGE followed by
autoradiography. (C) In vitro-translated Rb or mutated Rb (C706F) proteins
were used in binding to GST–BRCA1 fragments as described in B. One-fifth of
the input was loaded in the IVT lane.
Fig. 7. Rb interacts with BRCA1 protein. (A and C) Pull-down assay with the
use of recombinant GST–Rb or GST–BRCA1 polypeptides. GST fusion proteins
were incubated with U2OS (A) or SK-N-SH (C) cell lysates, and bound BRCA1 or
Rb proteins were identified by Western blot (WB). Protein (100 mg) was loaded
into WCE lanes. Approximately 1 mg of protein was used for each pull-down
reaction. In A, GST-Grb7 protein was used as a negative control; in the last
lane, the GST–RbABC/BRCA1 protein complex was released from the gluta-
thione–Sepharose with glutathione (GSH) before loading as described in
Methods. (B and D) Coimmunoprecipitation of pRb and BRCA1. Rb or BRCA1
proteins were immunoprecipitated from U2OS cell lysate by using anti-Rb
(C-36 or C-15) (B) or anti-BRCA1 (MS110) (D). Normal mouse or rabbit IgG or
anti-CD54 antibody was used as a negative control. Total protein (100 mg) was
loaded into WCE lanes and ' 2 mg of protein was used for each immunopre-
cipitation.
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truncation of BRCA1 was also ineffective in inhibiting colony
formation.
Discussion
We have found that the ability of BRCA1 to suppress growth
depends on the presence of a functional Rb protein. Although
pRb may be required for BRCA1-mediated growth arrest, we
recognize that this, in itself, is not evidence that the direct
biochemical interaction of the two proteins is responsible for
BRCA1 growth inhibition. pRb serves as a downstream effector
in several pathways associated with growth suppression, and
BRCA1 could presumably act upstream of pRb in any of these
pathways, requiring pRb only as the final acceptor of the
negative growth signal.
One intriguing candidate for downstream effector of BRCA1
growth inhibition appeared to be p21Waf1/Cip1. Evidence exists
showing that BRCA1 can activate the transcription of p21 even
in the absence of p53, suggesting a p53-independent pathway
(19). Our data show that this cannot be the only mechanism for
BRCA1-induced growth inhibition. First, no p21 protein induc-
tion was observed at low levels (2- to 5-fold) of BRCA1 over-
expression achieved in transfection of U2OS cells (data not
shown). Second, p21 induction blocked cell proliferation of Rb
negative SAOS-2 cells (20). Thus, we believe that at levels of
BRCA1 overexpression usually achieved in transfection experi-
ments, BRCA1 uses pathways other than a p21-mediated mech-
anism to block cell proliferation.
While the manuscript was in preparation, the association of
BRCA1 with components of the histone deacetylase complex was
reported (21). This finding provides yet another possible expla-
nation of how BRCA1 growth arrest may depend on Rb. The
complex of Rb with histone deacetylase is thought to suppress
transcription of E2F-responsive genes. BRCA1 may target this
complex to specific genes regulated by progression through the
cell cycle or after DNA damage or differentiation. The inhibition
of estrogen receptor signaling by overexpressed BRCA1 as
recently reported (22) also supports this hypothesis.
The BRCA1/Rb interaction may have interesting clinical ram-
ifications. If pRb is a biochemical modulator of BRCA1 action,
then it is conceivable that reductions in the level of pRb
expression in breast epithelia may induce a BRCA1 ‘‘null’’
phenocopy only in BRCA1 carriers with potentially reduced
BRCA1 expression. In this case, environmental or pharmaco-
logical factors that augment pRb expression may serve to delay
the onset of cancers in these susceptible women.
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of 90 aa (amino acids 303–394) or a COOH-terminal truncation. Each trans-
fection was done in triplicate in three independent experiments.
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